建模预测四个亚洲地区2019-2030年NAFLD疾病负担
该研究采用疾病进展模型,汇总并预测香港、新加坡、韩国和台湾NAFLD人群的纤维化进展,利用成人肥胖患病率变化外推NAFLD发病率长期趋势。结果显示2019-2030年NAFLD患病病例预计增加6%-20%,NASH病例增加20%-35%,肝细胞癌和失代偿期肝硬化发病率及NAFLD相关死亡率均大幅上升。
要点
- 2019-2030年四个亚洲地区NAFLD和NASH患病病例预计显著增加。
- 肝细胞癌、失代偿期肝硬化和NAFLD相关死亡率预计大幅上升。
- 控制糖尿病和肥胖人群增长是减轻NAFLD疾病负担的关键。
核心结论
- 预防糖尿病和肥胖人群的增长是减少亚太地区NAFLD相关疾病负担持续增加的关键因素。
研究设计与样本
- 采用疾病进展模型,汇总并预测香港、新加坡、韩国和台湾NAFLD人群的纤维化进展。
- 利用各区域成人肥胖患病率变化外推NAFLD发病率的长期趋势。
主要发现
- 在所研究区域,2019-2030年流行NAFLD病例预计增加6%-20%。
- 流行NASH病例预计增加20%-35%。
- 肝细胞癌发病病例预计增加65%-85%。
- 失代偿期肝硬化发病病例预计增加65%-100%。
- NAFLD相关死亡率预计从2019年到2030年增加65%-100%。
临床怎么用
- 临床应关注NAFLD患者中纤维化进展高风险人群,以应对预计增加的晚期肝病和死亡。
- 在亚太地区,控制糖尿病和肥胖流行可能有助于减缓NAFLD疾病负担增长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia-Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations. AIMS: To estimate using modelling the growth in NAFLD populations, including cases with significant fibrosis that are most likely to experience advanced liver disease and related mortality. METHODS: A disease progression model was used to summarise and project fibrosis progression among the NAFLD populations of Hong Kong, Singapore, South Korea and Taiwan. For each area, changes in the adult prevalence of obesity was used to extrapolate long-term trends in NAFLD incidence. RESULTS: In the areas studied, prevalent NAFLD cases were projected to increase 6%-20% during 2019-2030, while prevalent NASH cases increase 20%-35%. Incident cases of hepatocellular carcinoma are projected to increase by 65%-85%, while incident decompensated cirrhosis cases increase 65%-100% by 2030. Likewise, NAFLD-related mortality is projected to increase between 65% and 100% from 2019 to 2030. NAFLD disease burden is expected to increase alongside rising trends in metabolic syndrome and obesity among populations in the region. This leads to more cases of advanced liver disease and associated mortality. CONCLUSIONS: Preventing the growth of diabetic and obese populations will be a key factor in reducing ongoing increases in NAFLD-related disease burden in the Asia-Pacific region.
引用
- Estes C, Chan HLY, Chien RN, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther. 2020. PMID: 32133676. doi:10.1111/apt.15673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。